| Year |
Citation |
Score |
| 2023 |
Gironda DJ, Bergan RC, Alpaugh RK, Danila DC, Chuang TL, Hurtado BY, Ho T, Adams DL. Cancer Associated Macrophage-like Cells Are Prognostic for Highly Aggressive Prostate Cancer in Both the Non-Metastatic and Metastatic Settings. Cancers. 15. PMID 37509385 DOI: 10.3390/cancers15143725 |
0.427 |
|
| 2022 |
Johnson BE, Creason AL, Stommel JM, Keck JM, Parmar S, Betts CB, Blucher A, Boniface C, Bucher E, Burlingame E, Camp T, Chin K, Eng J, Estabrook J, Feiler HS, ... ... Bergan R, et al. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Reports. Medicine. 3: 100525. PMID 35243422 DOI: 10.1016/j.xcrm.2022.100525 |
0.323 |
|
| 2021 |
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, ... ... Bergan R, et al. Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. Npj Precision Oncology. 5: 92. PMID 34667258 DOI: 10.1038/s41698-021-00232-w |
0.324 |
|
| 2020 |
Graff JN, Beer TM, Alumkal JJ, Slottke RE, Redmond WL, Thomas GV, Thompson RF, Wood MA, Koguchi Y, Chen Y, Latour E, Bergan RC, Drake CG, Moran AE. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. Journal For Immunotherapy of Cancer. 8. PMID 32616555 DOI: 10.1136/Jitc-2020-000642 |
0.507 |
|
| 2020 |
Zhang X, Zhang Z, Cao M, Liu B, Mori M, Luoh SW, Bergan R, Liu Y, Liu Y. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer. Clinical Breast Cancer. PMID 32482525 DOI: 10.1016/J.Clbc.2020.04.009 |
0.338 |
|
| 2020 |
Li A, Labrie M, Vuky J, Lim JY, Johnson B, Sivagnanam S, Betts C, Coussens L, Corless CL, Bergan RC, Gray JW, Mills GB, Mitri ZI. Feasibility of real-time serial comprehensive tumor analytics: Pilot study of olaparib and durvalumab in metastatic triple negative breast cancer (mTNBC). Journal of Clinical Oncology. 38: e13092-e13092. DOI: 10.1200/Jco.2020.38.15_Suppl.E13092 |
0.336 |
|
| 2020 |
Adams D, Lin SH, Pass HI, Chumsri S, Lapidus RG, Edelman M, Bergan RC, Tsai S, Aft R, Pillai S, Watson M, Kim AK, Chikamatsu K, Hayashi M, Loeb DM, et al. Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors. Journal of Clinical Oncology. 38: 3535-3535. DOI: 10.1200/Jco.2020.38.15_Suppl.3535 |
0.375 |
|
| 2019 |
Zhang Z, Bien J, Mori M, Jindal S, Bergan R. A way forward for cancer prevention therapy: personalized risk assessment. Oncotarget. 10: 6898-6912. PMID 31839883 DOI: 10.18632/Oncotarget.27365 |
0.353 |
|
| 2019 |
Bergan R, Xu L, Zhang Y, Xue X, Liu J, Li ZS, Yang GY, Song Y, Pan Y, Ma Y, Hu S, Wen A, Jia Y, Rodriguez LM, Tull MB, et al. A Phase I Trial of Berberine in Chinese with Ulcerative Colitis. Cancer Prevention Research (Philadelphia, Pa.). PMID 31619442 DOI: 10.1158/1940-6207.Capr-19-0258 |
0.31 |
|
| 2019 |
Zhang L, Pattanayak A, Li W, Ko HK, Fowler G, Gordon R, Bergan R. A multi-functional therapy approach for cancer: targeting Raf1- mediated inhibition of cell motility, growth and interaction with the microenvironment. Molecular Cancer Therapeutics. PMID 31582531 DOI: 10.1158/1535-7163.Mct-19-0222 |
0.532 |
|
| 2019 |
Mishra RK, Deibler KK, Clutter MR, Vagadia PP, O'Connor M, Schiltz GE, Bergan R, Scheidt KA. Modeling MEK4 Kinase Inhibitors Through Perturbed Electrostatic Potential (ESP) Charges. Journal of Chemical Information and Modeling. PMID 31566378 DOI: 10.1021/Acs.Jcim.9B00490 |
0.408 |
|
| 2019 |
Thrivikraman G, Athirasala A, Gordon R, Zhang L, Bergan R, Keene DR, Jones JM, Xie H, Chen Z, Tao J, Wingender B, Gower L, Ferracane JL, Bertassoni LE. Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization. Nature Communications. 10: 3520. PMID 31388010 DOI: 10.1038/S41467-019-11455-8 |
0.35 |
|
| 2019 |
Li Y, Guo Y, Feng Z, Bergan R, Li B, Qin Y, Zhao L, Zhang Z, Shi M. Involvement of the PI3K/Akt/Nrf2 Signaling Pathway in Resveratrol-Mediated Reversal of Drug Resistance in HL-60/ADR Cells. Nutrition and Cancer. 1-12. PMID 31032633 DOI: 10.1080/01635581.2019.1578387 |
0.374 |
|
| 2019 |
Zhang H, Gordon R, Li W, Yang X, Pattanayak A, Fowler G, Zhang L, Catalona WJ, Ding Y, Xu L, Huang X, Jovanovic B, Kelly DL, Jiang H, Bergan R. Genistein treatment duration effects biomarkers of cell motility in human prostate. Plos One. 14: e0214078. PMID 30917169 DOI: 10.1371/Journal.Pone.0214078 |
0.498 |
|
| 2019 |
Scheidt K, Deibler KK, Schiltz GE, Clutter MR, Mishra RK, Vagadia PP, O'Connor M, George MD, Gordon R, Fowler G, Bergan R. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors. Chemmedchem. PMID 30707493 DOI: 10.1002/Cmdc.201900019 |
0.513 |
|
| 2019 |
Keck JM, Parmar S, Kong B, Mitri Z, Corless C, Kolodzie A, Creason A, Goecks J, Leyshock P, Siex K, Johnson BE, Patterson J, Heiser L, Olson A, Viehdorfer M, ... ... Bergan RC, et al. Abstract 4929: Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART Treatments Program Cancer Research. 79: 4929-4929. DOI: 10.1158/1538-7445.Sabcs18-4929 |
0.425 |
|
| 2019 |
Gordon R, Zhang L, Pattanayak A, Li W, Bergan R. Abstract LB-C11: Targeting metastatic prostate cancer with a multi-functional therapy approach Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Lb-C11 |
0.548 |
|
| 2018 |
Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 933-937. PMID 30099369 DOI: 10.6004/Jnccn.2018.7020 |
0.355 |
|
| 2018 |
Xu L, Gordon R, Farmer R, Pattanayak A, Binkowski A, Huang X, Avram M, Krishna S, Voll E, Pavese J, Chavez J, Bruce J, Mazar A, Nibbs A, Anderson W, ... ... Bergan R, et al. Precision therapeutic targeting of human cancer cell motility. Nature Communications. 9: 2454. PMID 29934502 DOI: 10.1038/S41467-018-04465-5 |
0.801 |
|
| 2018 |
Zhang Z, Bergan R, Shannon J, Slatore CG, Bobe G, Takata Y. The Role of Cruciferous Vegetables and Isothiocyanates for Lung Cancer Prevention: Current Status, Challenges and Future Research Directions. Molecular Nutrition & Food Research. e1700936. PMID 29663679 DOI: 10.1002/Mnfr.201700936 |
0.368 |
|
| 2018 |
Wali RK, Bianchi L, Kupfer S, De La Cruz M, Jovanovic B, Weber C, Goldberg MJ, Rodriguez LM, Bergan R, Rubin D, Tull MB, Richmond E, Parker B, Khan S, Roy HK. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. Plos One. 13: e0193544. PMID 29617381 DOI: 10.1371/Journal.Pone.0193544 |
0.312 |
|
| 2018 |
Adams D, Bergan RC, Alpaugh RK, Martin SS, Edelman MJ, Lapidus RG, Chumsri S, Cristofanilli M, Tang C, Lin SH. Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers. Journal of Clinical Oncology. 36: 12032-12032. DOI: 10.1200/Jco.2018.36.15_Suppl.12032 |
0.456 |
|
| 2018 |
Johnson B, Keck J, Morris M, Siex K, Kolodzie A, Parmar S, Riesterer J, Chin K, Gibbs S, Heiser L, Spellman P, Ellrott K, Babur O, Demir E, Margolin A, ... ... Bergan R, et al. Abstract 3296: SMMART: Serial measurements of molecular and architectural responses to therapy Cancer Research. 78: 3296-3296. DOI: 10.1158/1538-7445.Am2018-3296 |
0.472 |
|
| 2018 |
Adams DL, Lin SH, Alpaugh RK, Ho T, Marks JR, Martin SS, Tsai S, Chumsri S, Tang C, Cristofanilli M, Bergan R. Abstract 2631: Cancer associated macrophage-like (CAMLs) cells in blood predict progression and survival for all stages of solid tumors Cancer Research. 78: 2631-2631. DOI: 10.1158/1538-7445.Am2018-2631 |
0.413 |
|
| 2017 |
Marshall JR, Burk RF, Ondracek RP, Hill KE, Perloff M, Davis W, Pili R, George S, Bergan R. Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget. PMID 28412747 DOI: 10.18632/Oncotarget.15460 |
0.456 |
|
| 2017 |
Deibler KK, Mishra RK, Clutter MR, Antanasijevic A, Bergan R, Caffrey M, Scheidt KA. A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK kinase Family. Acs Chemical Biology. PMID 28263556 DOI: 10.1021/Acschembio.6B01060 |
0.411 |
|
| 2017 |
Adams D, Adams DK, Lin SH, Cristofanilli M, Bergan RC, Marks JR, Martin SS, Chumsri S, Ho TH, Lapidus RG, Tsai S, Tang C, Alpaugh RK. Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies. Journal of Clinical Oncology. 35: 11503-11503. DOI: 10.1200/Jco.2017.35.15_Suppl.11503 |
0.377 |
|
| 2017 |
Adams DL, Alpaugh RK, Lin SH, Marks JR, Bergan R, Martin SS, Chumsri S, Cristofanilli M, Tang C, Stefansson S. Abstract 778: Identifying, subtyping and classifying tumor associated circulating endothelial cells in patients with solid tumors Cancer Research. 77: 778-778. DOI: 10.1158/1538-7445.Am2017-778 |
0.317 |
|
| 2017 |
Adams DL, Alpaugh RK, Ho TH, Lin SH, Marks JR, Bergan R, Martin SS, Chumsri S, Tang C, Cristofanilli M. Abstract 3798: Multiplex phenotyping of circulating cancer associated macrophage-like cells in patients with solid tumors Cancer Research. 77: 3798-3798. DOI: 10.1158/1538-7445.Am2017-3798 |
0.435 |
|
| 2016 |
Al Rabadi L, Bergan R. A Way Forward for Cancer Chemoprevention: Think Local. Cancer Prevention Research (Philadelphia, Pa.). 10: 14-35. PMID 27780807 DOI: 10.1158/1940-6207.Capr-16-0194 |
0.421 |
|
| 2016 |
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. PMID 27429197 DOI: 10.18632/Oncotarget.10547 |
0.424 |
|
| 2015 |
Hou L, Joyce BT, Gao T, Liu L, Zheng Y, Penedo FJ, Liu S, Zhang W, Bergan R, Dai Q, Vokonas P, Hoxha M, Schwartz J, Baccarelli A. Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort. Ebiomedicine. 2: 591-6. PMID 26288820 DOI: 10.1016/J.Ebiom.2015.04.008 |
0.418 |
|
| 2015 |
Xiao X, Liu Z, Wang R, Wang J, Zhang S, Cai X, Wu K, Bergan RC, Xu L, Fan D. Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis. Oncotarget. 6: 3225-39. PMID 25605009 DOI: 10.18632/Oncotarget.3064 |
0.498 |
|
| 2014 |
Moazzem Hossain M, Wang X, Bergan RC, Jin JP. Diminished expression of h2-calponin in prostate cancer cells promotes cell proliferation, migration and the dependence of cell adhesion on substrate stiffness. Febs Open Bio. 4: 627-36. PMID 25161871 DOI: 10.1016/J.Fob.2014.06.003 |
0.498 |
|
| 2014 |
Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B, Bergan RC. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. Plos One. 9: e102289. PMID 25019290 DOI: 10.1371/Journal.Pone.0102289 |
0.827 |
|
| 2014 |
Pavese JM, Bergan RC. Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. Cancer Letters. 352: 179-86. PMID 25016063 DOI: 10.1016/J.Canlet.2014.06.012 |
0.836 |
|
| 2014 |
Pavese JM, Krishna SN, Bergan RC. Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis. The American Journal of Clinical Nutrition. 100: 431S-6S. PMID 24871471 DOI: 10.3945/Ajcn.113.071290 |
0.833 |
|
| 2014 |
Voll EA, Ogden IM, Pavese JM, Huang X, Xu L, Jovanovic BD, Bergan RC. Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression. Oncotarget. 5: 2648-63. PMID 24798191 DOI: 10.18632/Oncotarget.1917 |
0.819 |
|
| 2014 |
Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 111: 3514-9. PMID 24550495 DOI: 10.1073/Pnas.1320198111 |
0.451 |
|
| 2014 |
Simon MA, de la Riva EE, Bergan R, Norbeck C, McKoy JM, Kulesza P, Dong X, Schink J, Fleisher L. Improving diversity in cancer research trials: the story of the Cancer Disparities Research Network. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. 29: 366-74. PMID 24519744 DOI: 10.1007/S13187-014-0617-Y |
0.315 |
|
| 2014 |
Krishna SN, Bergan RC. Therapeutic modulation of prostate cancer metastasis. Future Medicinal Chemistry. 6: 223-39. PMID 24467245 DOI: 10.4155/Fmc.13.201 |
0.843 |
|
| 2014 |
Adams D, Bergan RC, Ogden IM, Alpaugh RK, Cristofanilli M, Makarova OV, Zhu P, Li S, Amstutz PT, Tang C. A pilot study detailing cancer-specific biomarkers in giant macrophages mimicking circulating tumor cells in the circulation of cancer patients. Journal of Clinical Oncology. 32: e22015-e22015. DOI: 10.1200/Jco.2014.32.15_Suppl.E22015 |
0.514 |
|
| 2014 |
Adams D, Martin SS, Charpentier M, Chumsri S, Bergan RC, Ogden IM, Alpaugh RK, Cristofanilli M, Tsai S, Makarova OV, Zhu P, Li S, Amstutz PT, Tang C. A pilot study identifying cancer-associated macrophage-like cells in the blood of cancer patients. Journal of Clinical Oncology. 32: e22014-e22014. DOI: 10.1200/Jco.2014.32.15_Suppl.E22014 |
0.495 |
|
| 2014 |
Krishna SN, Luan C, Clutter MR, Mishra RK, Scheidt KA, Anderson WF, Bergan RC. Abstract 5394: A high-throughput screening platform for the identification of small molecule inhibitors of MAP2K4 Cancer Research. 74: 5394-5394. DOI: 10.1158/1538-7445.Am2014-5394 |
0.831 |
|
| 2013 |
Krishna SN, Luan CH, Mishra RK, Xu L, Scheidt KA, Anderson WF, Bergan RC. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4. Plos One. 8: e81504. PMID 24339940 DOI: 10.1371/Journal.Pone.0081504 |
0.823 |
|
| 2013 |
Pavese J, Ogden IM, Bergan RC. An orthotopic murine model of human prostate cancer metastasis. Journal of Visualized Experiments : Jove. e50873. PMID 24084571 DOI: 10.3791/50873 |
0.837 |
|
| 2013 |
Breen MJ, Moran DM, Liu W, Huang X, Vary CP, Bergan RC. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. Plos One. 8: e72407. PMID 23967299 DOI: 10.1371/Journal.Pone.0072407 |
0.464 |
|
| 2013 |
Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Research. 73: 3725-36. PMID 23539448 DOI: 10.1158/0008-5472.Can-12-3468 |
0.572 |
|
| 2013 |
Light SH, Krishna SN, Bergan RC, Lavie A, Anderson WF. Crystal structure of a type II dehydroquinate dehydratase-like protein from Bifidobacterium longum. Journal of Structural and Functional Genomics. 14: 25-30. PMID 23539270 DOI: 10.1007/S10969-013-9149-7 |
0.759 |
|
| 2013 |
Dew A, Khan S, Babinski C, Michel N, Heffernan M, Stephan S, Jordan N, Jovanovic B, Carney P, Bergan R. Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial. Clinical Trials (London, England). 10: 292-9. PMID 23321266 DOI: 10.1177/1740774512471452 |
0.396 |
|
| 2013 |
Krishna SN, Luan C, Mishra RK, Xu L, Scheidt KA, Anderson WF, Bergan RC. Correction: A Fluorescence-Based Thermal Shift Assay Identifies Inhibitors of Mitogen Activated Protein Kinase Kinase 4 Plos One. 8. DOI: 10.1371/annotation/5edeb1de-b76c-4fd9-a3f6-0f1cf45e3905 |
0.777 |
|
| 2013 |
Adams D, Alpaugh RK, Cristofanilli M, Martin S, Chumsri S, Charpentier M, Bergan RC, Ogden IM, Tsai S, Zhu P, Makarova OV, Li S, Amstutz PT, Tang C. Abstract 1448: Identifying and subtyping circulating tumor cells from breast, prostate, and pancreatic cancer patients based on distinct morphology. Cancer Research. 73: 1448-1448. DOI: 10.1158/1538-7445.Am2013-1448 |
0.516 |
|
| 2013 |
Roy HK, Radosevich A, Wali RK, Umar A, Della'Zanna G, Janovic B, Goldberg MJ, Bianchi LK, Rubin DT, Rodriguez L, Tsang T, Turzhitsky V, Shklovskaya J, Skripkauskas S, Helenowski I, ... Bergan R, et al. Mo1161 Phase 2B Randomized Placebo-Controlled Spectral Markers As Biomarkers for Colonic Chemoprevention With Aspirin: Correlation With Rectal Apoptosis but Not Proliferation Gastroenterology. 144: S-595. DOI: 10.1016/S0016-5085(13)62194-0 |
0.441 |
|
| 2012 |
Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, ... ... Bergan RC, et al. Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase ii trial Cancer Prevention Research. 5: 309-319. PMID 22307566 DOI: 10.1158/1940-6207.Capr-11-0251 |
0.316 |
|
| 2012 |
Khan SA, Chatterton RT, Bergan R. Soy Isoflavones for Breast Cancer Risk Reduction--Response Cancer Prevention Research. 5: 986-987. DOI: 10.1158/1940-6207.Capr-12-0189 |
0.306 |
|
| 2012 |
Franzen CA, Pelling JC, Bergan RC. Abstract 615: Apigenin regulates prostate cancer matrix composition and cell attachment through an integrin alpha 1 dependent pathway Cancer Research. 72: 615-615. DOI: 10.1158/1538-7445.Am2012-615 |
0.514 |
|
| 2012 |
Voll E, Ogden I, Huang X, Bergan R. Abstract 5331: The effect of heat shock protein 27 (HSP27) on prostate cancer cell adhesion, invasion and metastasis Cancer Research. 72: 5331-5331. DOI: 10.1158/1538-7445.Am2012-5331 |
0.851 |
|
| 2012 |
Breen MJ, Moran DM, Bergan RC. Abstract 491: Endoglin suppresses prostate cancer invasion through two distinct type II TGF-β receptors Cancer Research. 72: 491-491. DOI: 10.1158/1538-7445.Am2012-491 |
0.485 |
|
| 2012 |
Xu L, Farmer R, Huang X, Pruell S, Voll E, Pavese J, Valsecchi M, Biddle M, Nibbs A, Avram M, Scheidt KA, Bergan RC. Abstract 4752: Selective inhibition of cancer metastasis with a novel small therapeutic molecule Cancer Research. 72: 4752-4752. DOI: 10.1158/1538-7445.Am2012-4752 |
0.821 |
|
| 2012 |
Krishna SN, Luan C, Minasov G, Shuvalova L, Farmer RL, Nibbs A, Scheidt KA, Anderson WF, Bergan RC. Abstract 4751: Structure and inhibition of mitogen-activated protein kinase kinase 4 (MEK4): A prostate cancer pro-invasion protein Cancer Research. 72: 4751-4751. DOI: 10.1158/1538-7445.Am2012-4751 |
0.852 |
|
| 2012 |
Pavese JM, Ogden I, Huang X, Bergan R. Abstract 3277: Increased mitogen-activated protein kinase kinase 4 (MEK4) induces metastasis in an orthotopic murine model of prostate cancer Cancer Research. 72: 3277-3277. DOI: 10.1158/1538-7445.Am2012-3277 |
0.844 |
|
| 2011 |
Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prevention Research (Philadelphia, Pa.). 4: 1938-44. PMID 21846796 DOI: 10.1158/1940-6207.Capr-10-0259 |
0.386 |
|
| 2011 |
Xu L, Wang SS, Healey MA, Faupel-Badger JM, Wilken JA, Battaglia T, Szabo E, Mao JT, Bergan RC. The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research. Cancer Prevention Research (Philadelphia, Pa.). 4: 616-21. PMID 21464034 DOI: 10.1158/1940-6207.Capr-11-0018 |
0.399 |
|
| 2011 |
Romero D, O'Neill C, Terzic A, Contois L, Young K, Conley BA, Bergan RC, Brooks PC, Vary CP. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Research. 71: 3482-93. PMID 21444673 DOI: 10.1158/0008-5472.Can-10-2665 |
0.54 |
|
| 2011 |
Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, Romero D, Vary CP, Bergan RC. Endoglin suppresses human prostate cancer metastasis. Clinical & Experimental Metastasis. 28: 39-53. PMID 20981476 DOI: 10.1007/S10585-010-9356-6 |
0.803 |
|
| 2011 |
Huang XK, Bergan R. Abstract 5244: Genistein's anti-invasion and anti-metastatic effects are linked to decreases in the expression of several different gene in Human prostate cancer that regulate metastatic behavior Cancer Research. 71: 5244-5244. DOI: 10.1158/1538-7445.Am2011-5244 |
0.437 |
|
| 2011 |
Pavese JM, Ogden IM, Huang X, Xu L, Bergan RC. Abstract 1407: Mitogen-activated protein kinase kinase 4 (MEK4) is a key regulator of prostate cancer progression Cancer Research. 71: 1407-1407. DOI: 10.1158/1538-7445.Am2011-1407 |
0.859 |
|
| 2011 |
Xu L, Farmer R, Huang X, Valsecchi M, Pavese J, Voll E, Biddle M, Nibbs A, Pruell S, Avram M, Scheidt K, Bergan RC. Abstract C177: Chemical-driven biological probing: Discovery of a novel antimetastatic drug. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C177 |
0.817 |
|
| 2011 |
Simon MA, Schink JC, Riva EEdl, Fleisher L, Norbeck C, Kandadai V, Davis SN, Bergan R, Beck R, Louden DM. Abstract B6: Region Five GMaP/BMaP Network: Preliminary findings from the comprehensive needs assessment biospecimen facility survey Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-B6 |
0.301 |
|
| 2011 |
Farmer RL, Biddle MM, Nibbs AE, Huang X, Xu L, Bergan RC, Scheidt KA. Erratum: Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression (ACS Medicinal Chemistry Letters (2010) 1 (400-405) DOI: 10.1021/ml100110x) Acs Medicinal Chemistry Letters. 2. DOI: 10.1021/Ml1003102 |
0.511 |
|
| 2011 |
Huang X, McGuire BB, Ogden I, O'Brien DC, Cooper PR, Banks JA, Catalona WJ, Bergan RC. 130 CIRCULATING TUMOR CELLS IN PROSTATE CANCER PATIENTS: NOVEL IMMUNOMAGNETIC ENRICHMENT METHOD Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.197 |
0.524 |
|
| 2011 |
McGuire BB, Huang X, Ogden I, O'Brien DC, Cooper PR, Banks JA, Catalona WJ, Bergan RC. 732 GENISTEIN INHIBITS PROSTATE CANCER METASTASIS BY PREVENTING CELL DETACHMENT Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1701 |
0.462 |
|
| 2010 |
Farmer RL, Biddle MM, Nibbs AE, Huang X, Bergan RC, Scheidt KA. Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression. Acs Medicinal Chemistry Letters. 1: 400-405. PMID 21116437 DOI: 10.1021/Ml100110X |
0.536 |
|
| 2010 |
Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Reviews. 29: 465-82. PMID 20730632 DOI: 10.1007/S10555-010-9238-Z |
0.856 |
|
| 2010 |
Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis. 31: 359-66. PMID 19736306 DOI: 10.1093/Carcin/Bgp217 |
0.798 |
|
| 2010 |
Bergan RC. Abstract CN02-04: Phase II study of genistein in men with prostate cancer Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-Cn02-04 |
0.579 |
|
| 2010 |
Xu L, Farmer R, huang x, Pavese J, Voll E, Irene O, Biddle M, Nibbs A, Valsecchi M, Scheidt K, Bergan R. Abstract B58: Discovery of a novel drug KBU2046 that inhibits conversion of human prostate cancer to a metastatic phenotype Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-B58 |
0.833 |
|
| 2009 |
Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, Jovanovic B, Wellman K, Killmer J, Huang X, Scheidt KA, Montgomery RB, Bergan RC. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. Journal of the National Cancer Institute. 101: 1141-55. PMID 19638505 DOI: 10.1093/Jnci/Djp227 |
0.601 |
|
| 2009 |
Khan S, Michel N, Bryk M, Chatterton R, Ivancic D, Zalles C, Hansen N, Bethke K, Jovanovic B, Bergan R. A Phase IIb Trial of Soy Isoflavone Supplementation To Decrease Breast Cell Proliferation in High Risk Women. Cancer Research. 69: 1049-1049. DOI: 10.1158/0008-5472.Sabcs-09-1049 |
0.334 |
|
| 2008 |
Paunesku T, Ke T, Dharmakumar R, Mascheri N, Wu A, Lai B, Vogt S, Maser J, Thurn K, Szolc-Kowalska B, Larson A, Bergan RC, Omary R, Li D, Lu ZR, et al. Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images. Nanomedicine : Nanotechnology, Biology, and Medicine. 4: 201-7. PMID 18567541 DOI: 10.1016/J.Nano.2008.04.004 |
0.334 |
|
| 2008 |
Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, Pelling JC, Bergan RC. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Research. 68: 2024-32. PMID 18339885 DOI: 10.1158/0008-5472.Can-07-1246 |
0.597 |
|
| 2008 |
Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Molecular Carcinogenesis. 47: 686-700. PMID 18240292 DOI: 10.1002/Mc.20421 |
0.517 |
|
| 2008 |
Craft CS, Xu L, Romero D, Vary CP, Bergan RC. Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Molecular Pharmacology. 73: 235-42. PMID 17951357 DOI: 10.1124/Mol.107.038935 |
0.808 |
|
| 2008 |
Bergan R. Abstract ED05-02: Discovering new drugs to inhibit prostate cancer metastasis Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Ed05-02 |
0.503 |
|
| 2007 |
Kim YL, Jacobs DR, Gross MD, Bergan RC, Gann PH, Liu K, Gapstur SM. Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 2781-3. PMID 18086788 DOI: 10.1158/1055-9965.Epi-07-0637 |
0.367 |
|
| 2007 |
Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Investigation. 25: 733-7. PMID 17952740 DOI: 10.1080/07357900701506573 |
0.363 |
|
| 2007 |
Craft CS, Romero D, Vary CP, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene. 26: 7240-50. PMID 17496924 DOI: 10.1038/Sj.Onc.1210533 |
0.801 |
|
| 2006 |
Ding Y, Xu L, Chen S, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Ananthanarayanan V, Bergan RC. Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer and Prostatic Diseases. 9: 379-91. PMID 16786039 DOI: 10.1038/Sj.Pcan.4500888 |
0.387 |
|
| 2006 |
Xu L, Bergan RC. Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Molecular Pharmacology. 70: 869-77. PMID 16772519 DOI: 10.1124/Mol.106.023861 |
0.531 |
|
| 2006 |
Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer. 106: 2459-65. PMID 16615097 DOI: 10.1002/Cncr.21880 |
0.51 |
|
| 2006 |
Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene. 25: 2987-98. PMID 16407830 DOI: 10.1038/Sj.Onc.1209337 |
0.543 |
|
| 2005 |
Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, Bergan RC. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Research. 65: 3470-8. PMID 15833883 DOI: 10.1158/0008-5472.Can-04-2807 |
0.556 |
|
| 2005 |
Kelley MJ, Glaser EM, Herndon JE, Becker F, Bhagat R, Zhang YJ, Santella RM, Carmella SG, Hecht SS, Gallot L, Schilder L, Crowell JA, Perloff M, Folz RJ, Bergan RC. Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 892-9. PMID 15824161 DOI: 10.1158/1055-9965.Epi-04-0585 |
0.318 |
|
| 2004 |
Brown J, Von Roenn J, O'Regan R, Bergan R, Badve S, Rademaker A, Feehan S, Petersen J, Patton M, Gradishar W. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 546. PMID 28016578 DOI: 10.1200/Jco.2004.22.14_Suppl.546 |
0.466 |
|
| 2004 |
Simpson L, Bergan R, He X, Pins M, Perlman E, Campbell S, Huang X. ABL gene amplification is associated with renal medullary carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4549. PMID 28016043 DOI: 10.1200/Jco.2004.22.90140.4549 |
0.38 |
|
| 2004 |
Arnsmeier SL, Spies S, Shervin D, Pins M, Bergan RC. Phase I/II study of taxane and estramustine with samarium in patients with hormone refractory prostate cancer Journal of Clinical Oncology. 22: 4732-4732. DOI: 10.1200/jco.2004.22.90140.4732 |
0.338 |
|
| 2004 |
Arnsmeier SL, Spies S, Shervin D, Pins M, Bergan RC. Phase I/II study of taxane and estramustine with samarium in patients with hormone refractory prostate cancer Journal of Clinical Oncology. 22: 4732-4732. DOI: 10.1200/JCO.2004.22.14_SUPPL.4732 |
0.338 |
|
| 2003 |
Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene. 22: 4841-50. PMID 12894225 DOI: 10.1038/Sj.Onc.1206730 |
0.484 |
|
| 2002 |
Jovanovic BD, Huang S, Liu Y, Naguib KN, Bergan RC. An analysis of gene array data related to cell adhesion and prostate cancer. Cancer Treatment and Research. 113: 91-111. PMID 12613352 DOI: 10.1007/978-1-4757-3571-0_6 |
0.463 |
|
| 2002 |
Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene. 21: 8272-81. PMID 12447690 DOI: 10.1038/Sj.Onc.1206117 |
0.549 |
|
| 2001 |
Liu YQ, Kyle E, Patel S, Housseau F, Hakim F, Lieberman R, Pins M, Blagosklonny MV, Bergan RC. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer and Prostatic Diseases. 4: 81-91. PMID 12497043 DOI: 10.1038/Sj.Pcan.4500506 |
0.524 |
|
| 2001 |
Jovanovic BD, Huang S, Liu Y, Naguib KN, Bergan RC. A simple analysis of gene expression and variability in gene arrays based on repeated observations. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 1: 145-52. PMID 12174675 DOI: 10.2165/00129785-200101020-00007 |
0.313 |
|
| 2001 |
Bergan RC, Waggle DH, Carter SK, Horak I, Slichenmyer W, Meyers M. Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer Urology. 57: 77-80. PMID 11295600 DOI: 10.1016/S0090-4295(00)00946-8 |
0.507 |
|
| 2001 |
Liu Y, Bergan R. Improved Intracellular Delivery of Oligonucleotides by Square Wave Electroporation Antisense & Nucleic Acid Drug Development. 11: 7-14. PMID 11258623 DOI: 10.1089/108729001750072083 |
0.313 |
|
| 2001 |
Nabhan C, Bergan R. Chemoprevention in prostate cancer. Cancer Treatment and Research. 106: 103-36. PMID 11225000 DOI: 10.1007/978-1-4615-1657-6_5 |
0.519 |
|
| 2000 |
Liu Y, Kyle E, Lieberman R, Crowell J, Kellof G, Bergan RC. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation. Clinical & Experimental Metastasis. 18: 203-12. PMID 11315093 DOI: 10.1023/A:1006729106034 |
0.521 |
|
| 2000 |
Lee C, Janulis L, Ilio K, Shah A, Park I, Kim S, Cryns V, Pins M, Bergan R. In vitro models of prostate apoptosis: clusterin as an antiapoptotic mediator. The Prostate. Supplement. 9: 21-4. PMID 11056498 DOI: 10.1002/1097-0045(2000)45:9+<21::Aid-Pros5>3.0.Co;2-C |
0.42 |
|
| 1998 |
Schwartz GN, Liu YQ, Tisdale J, Walshe K, Fowler D, Gress R, Bergan RC. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity. Antisense & Nucleic Acid Drug Development. 8: 329-39. PMID 9743470 DOI: 10.1089/Oli.1.1998.8.329 |
0.393 |
|
| 1998 |
Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). The Prostate. 37: 51-9. PMID 9721069 DOI: 10.1002/(Sici)1097-0045(19980915)37:1<51::Aid-Pros8>3.0.Co;2-B |
0.521 |
|
| 1998 |
Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer Tumori Journal. 84: 87-89. DOI: 10.1177/030089169808400120 |
0.503 |
|
| 1997 |
Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Molecular Pharmacology. 51: 193-200. PMID 9203623 DOI: 10.1124/Mol.51.2.193 |
0.514 |
|
| 1997 |
Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1470-7. PMID 9193342 DOI: 10.1200/Jco.1997.15.4.1470 |
0.505 |
|
| 1996 |
Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin. Clinical & Experimental Metastasis. 14: 389-98. PMID 8878413 DOI: 10.1007/Bf00123398 |
0.57 |
|
| 1996 |
Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 76: 453-62. PMID 8625127 DOI: 10.1002/1097-0142(19950801)76:3<453::Aid-Cncr2820760316>3.0.Co;2-E |
0.487 |
|
| 1996 |
Bergan R, Hakim F, Schwartz G, Kyle E, Cepada R, Szabo J, Fowler D, Gress R, Neckers L. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging Blood. 88: 731-741. DOI: 10.1182/Blood.V88.2.731.Bloodjournal882731 |
0.381 |
|
| 1996 |
Bergan R, Neckers L. How do antisense oligodeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? Response Blood. 87: 4019-4020. DOI: 10.1182/Blood.V87.9.4019.Bloodjournal8794019 |
0.305 |
|
| 1995 |
Bergan RC, Kyle E, Connell Y, Neckers L. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Research and Development. 5: 33-8. PMID 7542047 DOI: 10.1089/Ard.1995.5.33 |
0.412 |
|
| 1995 |
Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. The American Journal of Medicine. 98: 412-4. PMID 7535978 DOI: 10.1016/S0002-9343(99)80323-4 |
0.444 |
|
| 1994 |
Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer. 74: 1612-4. PMID 8062193 DOI: 10.1002/1097-0142(19940901)74:5<1612::Aid-Cncr2820740519>3.0.Co;2-Q |
0.379 |
|
| 1994 |
Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L. Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Research. 22: 2150-4. PMID 8029025 DOI: 10.1093/Nar/22.11.2150 |
0.386 |
|
| 1993 |
Bergan R, Connell Y, Fahmy B, Neckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Research. 21: 3567-73. PMID 8346033 DOI: 10.1093/Nar/21.15.3567 |
0.366 |
|
| Show low-probability matches. |